The Path, founded by Tony Robbins and Calm alums, hopes to offer safer AI therapy

The Vera-MH benchmark that The Path is citing as proof of safety appears to be a relatively new and narrowly adopted evaluation instrument, which means the 95 score is essentially a company marketing itself using a scorecard the broader clinical or research community has not yet stress-tested or independently validated. The 46-point gap over 'leading consumer chatbots' also goes unattributed, so readers cannot verify which products were compared or under what conditions.

This is largely disconnected from recent activity in our archive. It belongs to a growing cluster of mental health AI launches where safety framing is doing commercial work, a pattern visible across the sector as regulators in the US and EU begin scrutinizing consumer-facing therapy tools more closely. The relevant question is not whether The Path scores well on Vera-MH, but whether Vera-MH will earn the kind of third-party legitimacy that clinical buyers actually require before procurement.

Watch whether any hospital system, insurer, or academic medical center cites Vera-MH scores in a procurement decision within the next 12 months. If that happens, the benchmark has real traction; if adoption stays confined to startup marketing materials, the safety differentiation story collapses.